Comparative Pharmacology
Head-to-head clinical analysis: ALPRAZOLAM versus NIRAVAM.
Head-to-head clinical analysis: ALPRAZOLAM versus NIRAVAM.
ALPRAZOLAM vs NIRAVAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Positive allosteric modulator of GABA-A receptors; enhances GABA inhibitory neurotransmission by binding to benzodiazepine site on GABA-A receptor, increasing chloride ion conductance.
NIRAVAM (alprazolam) is a benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and decreased excitability.
0.25-0.5 mg orally 3 times daily; maximum 4 mg/day in divided doses.
0.25–0.5 mg sublingually every 6–8 hours as needed; maximum 2 mg/day.
None Documented
None Documented
12-15 hours (mean ~13 hours); prolonged in elderly (up to 19 hours) and hepatic impairment (up to 20-30 hours); clinical context: allows once- to twice-daily dosing, but risk of accumulation with high doses or in vulnerable populations
Clinical Note
moderateAlprazolam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Alprazolam is combined with Fluticasone propionate."
Clinical Note
moderateAlprazolam + Haloperidol
"The risk or severity of adverse effects can be increased when Alprazolam is combined with Haloperidol."
Clinical Note
moderateAlprazolam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Alprazolam."
Clinical Note
moderateAlprazolam + Erythromycin
Terminal elimination half-life: 8–14 hours (mean 10.5 h). Clinically, steady-state reached in ~3 days; accumulation minimal at typical dosing.
Renal (approximately 80% as metabolites, <20% unchanged); fecal (minor, ~7%)
Renal: ~90% as metabolites (glucuronide conjugates and oxidized products), <5% unchanged. Fecal: <10%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The serum concentration of Erythromycin can be increased when it is combined with Alprazolam."